Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer.

Trial Profile

Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Carboplatin (Primary) ; Docetaxel (Primary) ; Cyclophosphamide; Epirubicin
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Feb 2017 Status changed from recruiting to completed.
    • 07 Jun 2016 Interim results (n=298) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2012 The study was activated in June 2010 with enrolment of 110 subjects.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top